Menu Search

Company Announcements

Know Labs Inc

Know Labs, Inc. Reports Fourth Quarter and Fiscal Year 2024 Results

SEATTLE--(BUSINESS WIRE)--Nov. 15, 2024-- Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the fourth quarter and fiscal year ended September 30, 2024.

Financial Highlights:

  • Know Labs reported a net loss of $16.58 million dollars in FY2024, compared to a net loss of $15.29 million dollars in FY2023, an increase in net loss of 8.4%. This translates to Earnings Per Share of a loss of $0.20, better than FY2023 Earnings Per Share Loss of $0.41, an improvement of 51%, before preferred stock dividends.
  • In FY2024, recorded a non-cash charge to earnings of $4.93 million, compared to $4.77 million FY2023. The non-cash items include (i) depreciation and amortization of $81,000; (ii) stock based compensation-stock options of $2,958,000; (iii) issuance of common stock for services of $277,000; (iv) amortization of operating lease right-of-use asset of $189,000; amortization of debt issuance costs of $831,000; and (v) interest expense for extension of notes and warrants of $594,000.
  • Research and development expense for FY2024 was $6.11 million dollars as compared to $7.73 million dollars in FY2023, a decrease of 21.0% year over year. The decrease in R&D expense was related to decreases in engineering, third-party technical services, and expenditures related to the development of our Generation 2 device, which we completed and announced on February 27, 2024, as we continue to execute our path to FDA clinical trials and commercialization.
  • Selling, general and administrative expenses for the year ended September 30, 2024 increased $2,538,000 to $9,109,000 as compared to $6,571,000 for the year ended September 30, 2023. The increase primarily was due to (i) an increase of $1,257,000 in salaries; (ii) an increase in legal expenses of $669,000; (iii) issuance of common stock for services of $277,000; and (iv) an increase in other expenses of $335,000. As part of the selling, general and administrative expenses for the years ended September 30, 2024 and 2023, we recorded $606,000 and $305,000, respectively, of investor relationship and business development expenses.
  • As of September 30, 2024, we have cash and cash equivalents of $3.11 million, as compared to $8.02 million dollars at the end of September 30, 2023. Net cash used in operations for FY2024 was $12.83 million dollars compared with $10.35 million in the prior year.
  • During the year ended September 30, 2024, the Company made adjustments to its fixed expenses and the impact of those adjustments has significantly reduced our monthly burn rate. Given the significant reduction in fixed expenses, the Company believes that it has enough available cash and flexibility with its operating expenses to operate through February 28, 2025. As we have stated in our FY2024 10-K, we expect to raise additional funds through the issuance of equity, preferred stock and convertible debentures.
  • Shareholder equity for the fiscal year 2024 was -$2.16 million versus $3.74 million in fiscal year 2023.

Income Statement:

Years Ended,
September 30, 2024 September 30, 2023
OPERATING EXPENSES-
RESEARCH AND DEVELOPMENT EXPENSES $

6,114,121

 

$

7,727,467

 

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

9,109,362

 

6,570,597

 

SELLING AND TRANSACTIONAL COSTS FOR DIGITAL ASSETS

-

 

(274,019

)

Total operating expenses

15,223,483

 

14,024,045

 

OPERATING LOSS

(15,223,483

)

(14,024,045

)

 
OTHER INCOME (EXPENSE), NET
Interest income

155,248

 

127,145

 

Interest expense

(1,513,323

)

(389,626

)

Loss on debt extinguishment

-

 

(506,865

)

Other (expense)

-

 

(495,776

)

Total other (expense), net

(1,358,075

)

(1,265,122

)

 
LOSS BEFORE INCOME TAXES

(16,581,558

)

(15,289,167

)

 
Income tax expense

-

 

-

 

 
NET LOSS

(16,581,558

)

(15,289,167

)

 
Deemed dividends on Series C and D Preferred Stock

(313,536

)

(3,526,653

)

Common stock dividends on Series D Preferred Stock

-

 

(1,627,230

)

 
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $

(16,895,094

)

$

(20,443,050

)

 
Basic and diluted loss per share $

(0.20

)

$

(0.41

)

 
Weighted average shares of common stock outstanding- basic and diluted

86,067,999

 

49,581,467

 

Balance Sheet:

September 30, 2024 September 30, 2023
ASSETS
 
CURRENT ASSETS:
Cash and cash equivalents $

3,110,755

 

$

8,023,716

 

Total current assets

3,110,755

 

8,023,716

 

 
PROPERTY AND EQUIPMENT, NET

66,796

 

81,325

 

 
OTHER ASSETS
Other assets

149,174

 

15,766

 

Operating lease right-of-use asset

337,703

 

145,090

 

 
TOTAL ASSETS $

3,664,428

 

$

8,265,897

 

 
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
 
CURRENT LIABILITIES:
Accounts payable - trade $

552,680

 

$

1,292,861

 

Accrued expenses

101,582

 

94,062

 

Accrued expenses - related parties

84,573

 

218,334

 

Current portion of convertible notes payable, net

2,855,058

 

1,301,005

 

Current portion of convertible notes payable - related parties

1,460,926

 

1,460,926

 

Current portion of operating lease right-of-use liability

108,560

 

154,797

 

Total current liabilities

5,163,379

 

4,521,985

 

 
NON-CURRENT LIABILITIES:
Operating lease liability, net of current portion

249,728

 

-

 

Non-current portion of convertible notes payable, net

407,522

 

-

 

Total liabilities

5,820,629

 

4,521,985

 

 
COMMITMENTS AND CONTINGENCIES (Note 11)
 
STOCKHOLDERS’ (DEFICIT) EQUITY
Preferred stock - $0.001 par value, 5,000,000 shares authorized, Series C and D shares issued and outstanding as follows:
Series C Convertible Preferred stock $0.001 par value, 30,000 shares authorized, 17,858 shares issued and outstanding at 9/30/2024 and 9/30/2023, respectively

1,790

 

1,790

 

Series D Convertible Preferred stock $0.001 par value, 20,000 shares authorized, 10,161 shares issued and outstanding at 9/30/2024 and 9/30/2023, respectively

1,015

 

1,015

 

Common stock - $0.001 par value, 200,000,000 shares authorized, 108,097,936 and 80,358,463 shares issued and outstanding at 9/30/2024 and 9/30/2023, respectively

108,021

 

80,358

 

Additional paid in capital

136,468,855

 

125,501,537

 

Accumulated deficit

(138,735,882

)

(121,840,788

)

Total stockholders' (deficit) equity

(2,156,201

)

3,743,912

 

 
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY $

3,664,428

 

$

8,265,897

 

Cash Flow:

Years Ended,
September 30, 2024 September 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $

(16,581,558

)

$

(15,289,167

)

Adjustments to reconcile net loss to net cash (used in) operating activities
Depreciation and amortization

80,881

 

313,019

 

Stock based compensation - stock option grants

2,957,559

 

2,955,933

 

Issuance of common stock for services

277,011

 

-

 

Gain on debt settlement

-

 

(50,000

)

Loss on disposal of assets

-

 

549,431

 

Loss on debt extinguishment

-

 

506,865

 

Amortization of operating lease right-of-use asset

189,286

 

142,840

 

Amortization of debt issuance costs

830,948

 

-

 

Interest expense for extension of notes and warrants

594,761

 

349,721

 

Changes in operating assets and liabilities:
Other long-term assets

(133,408

)

(1,999

)

Operating lease right-of-use liability

(178,408

)

(147,719

)

Accounts payable - trade and accrued expenses

(866,422

)

317,085

 

NET CASH (USED IN) OPERATING ACTIVITIES

(12,829,350

)

(10,353,991

)

 
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of research and development equipment

(66,352

)

(80,797

)

NET CASH (USED IN) INVESTING ACTIVITIES:

(66,352

)

(80,797

)

 
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from debt offering

3,764,129

 

-

 

Repayment of note payable

(720,000

)

-

 

Proceeds from issuance of common stock offering, net

5,193,262

 

5,472,791

 

Payments of debt offering

(262,450

)

-

 

Proceeds from issuance of common stock for warrant exercise

7,800

 

387,334

 

Proceeds from issuance of common stock for stock options exercise

-

 

4,687

 

NET CASH PROVIDED BY FINANCING ACTIVITIES

7,982,741

 

5,864,812

 

 
NET (DECREASE) IN CASH AND CASH EQUIVALENTS

(4,912,961

)

(4,569,976

)

 
CASH AND CASH EQUIVALENTS, beginning of period

8,023,716

 

12,593,692

 

 
CASH AND CASH EQUIVALENTS, end of period $

3,110,755

 

$

8,023,716

 

 
Supplemental disclosures of cash flow information:
Interest paid $

241,000

 

$

140,000

 

Taxes paid $

-

 

$

-

 

 
Supplemental disclosure of non-cash financing activity:
Deemed dividends on Series C and D Preferred Stock $

313,536

 

$

3,526,653

 

Common stock dividends on Series D Preferred Stock $

-

 

$

1,627,230

 

Warrants issued for debt offering $

2,110,731

 

$

-

 

Common stock issued for debt payment $

240,000

 

$

-

 

Issuance costs from common stock offering $

670,149

 

$

1,527,209

 

A copy of the form 10-K filed with the SEC can also be downloaded from the Company’s website. All holders, including stockholders and bondholders, can request and receive a hard copy of the complete audited financial statements free of charge. Requests must be submitted to ask@knowlabs.co.

About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology is designed to able to integrate into a variety of wearable, mobile or bench-top form factors. The Company believes that this patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The Company’s first expected application of the technology will be in a product marketed as a non-invasive glucose monitor. The device is designed to provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.

Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2024, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

Know Labs, Inc. Contact:
Jordyn Hujar
jordyn@knowlabs.co
Ph. (206) 629-6414

Source: Know Labs, Inc.